Form 4: ORIC CMO Pratik Multani Reports Stock Transactions

Oric Pharmaceuticals' Chief Medical Officer, Pratik Multani, reported the acquisition of common stock through RSU vesting and ESPP, alongside a sale of shares to cover tax obligations.

Summary

• Pratik S Multani, Chief Medical Officer of Oric Pharmaceuticals, Inc. (ORIC), reported transactions involving common stock and restricted stock units (RSUs).
• On December 15, 2025, Mr. Multani acquired 29,333 shares of common stock at a price of $0, primarily due to the vesting of RSUs, which included 2,771 shares acquired under the company's 2020 Employee Stock Purchase Plan.
• Following this acquisition, Mr. Multani beneficially owned 78,869 shares of common stock.
• On December 16, 2025, Mr. Multani disposed of 10,720 shares of common stock at a weighted average price of $9.0605; this sale was specifically to cover tax withholding obligations related to the RSU vesting and was not a discretionary sale.
• After the disposition, Mr. Multani's beneficial ownership of common stock stood at 68,149 shares.
• Several tranches of RSUs vested on December 15, 2025, leading to the conversion of 8,000, 10,000, and 11,333 derivative securities into common stock, with remaining derivative securities for these awards being 0, 10,000, and 22,667 respectively, indicating future vesting.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to equity compensation (RSU vesting and tax-related sales), which are neutral in terms of company performance or strategic direction. It does not indicate any significant positive or negative developments for the company.

Positives

• Acquisition of 29,333 shares of common stock through RSU vesting and the Employee Stock Purchase Plan (ESPP) demonstrates continued equity participation by a key executive.
• The acquisition of 2,771 shares under the 2020 Employee Stock Purchase Plan indicates ongoing participation in employee benefit programs.

Negatives

• Disposition of 10,720 shares of common stock, although stated to be for tax withholding obligations, reduces the executive's direct shareholding.

Future Outlook

Future vesting of restricted stock units is scheduled for December 15, 2026, and December 15, 2027, indicating continued equity compensation for the reporting person.

Industry Context

Routine insider transactions like RSU vesting and subsequent tax-related sales are common in the biotechnology and pharmaceutical industries, where equity compensation is a significant component of executive remuneration. This filing does not provide broader industry insights.

Comparison to Industry Standards

• The structure of equity compensation, including Restricted Stock Units (RSUs) and Employee Stock Purchase Plans (ESPPs), is standard practice across many publicly traded companies, particularly in high-growth sectors like biotechnology.
• The vesting schedules (e.g., 1/3 annually) are typical for long-term incentive plans designed to retain key talent.
• No specific comparable companies or projects are mentioned in the filing to allow for a direct comparison of results.

Related Party Transactions

• The transactions involve an executive and the company's securities, which are considered related party transactions in the broad sense of insider dealings, but no unusual or non-arm's length transactions are disclosed beyond standard equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine insider transactions. The sale for tax purposes is not a discretionary sale, so it does not signal a lack of confidence.
• Employees: The continued vesting of RSUs and participation in the ESPP highlight the company's ongoing equity compensation programs, which can be a positive for employee retention and motivation.

Next Steps

• Future vesting of remaining Restricted Stock Units on December 15, 2026, and December 15, 2027.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, specifically the vesting of restricted stock units and a subsequent non-discretionary sale of shares to cover tax obligations. It does not provide new material information regarding the company's operational performance, financial health, or strategic direction. Therefore, it offers no basis for a change in investment recommendation, and a 'hold' stance is appropriate as investors should rely on more comprehensive financial reports for investment decisions.

Keywords

ORIC, Oric Pharmaceuticals, Pratik Multani, Form 4, insider transaction, stock vesting, RSU, ESPP, Chief Medical Officer, equity compensation, tax withholding